COMPANY

Strykagen Corporation

HQ: Reno, NV source · strykagen.com ↗ · Mountain

Keywords: Duchenne muscular dystrophy Becker muscular dystrophy congenital muscular dystrophy

Location: Reno, NV · source · Oct 15, 2026

Profile checked Oct 10, 2026

8NIH grants

NIH awards 8

Annual award amounts. Total $4.1M.

Aug 16, 2024 NIH award 5R44OD030543-05 FY2024: $994,272 awarded for that fiscal year; activity R44 (SBIR); PI WUEBBLES, RYAN DAVID; recipient as written: STRYKAGEN CORPORATION, RENO, NV. Optimization of an integrin enhancing mole source ↗
Sep 15, 2023 NIH award 2R44OD030543-04 FY2023: $958,973 awarded for that fiscal year; activity R44 (SBIR); PI WUEBBLES, RYAN DAVID; recipient as written: STRYKAGEN CORPORATION, RENO, NV. Optimization of an integrin enhancing mole source ↗
Aug 16, 2021 NIH award 5R42OD030543-03 FY2021: $752,426 awarded for that fiscal year; activity R42 (STTR); PI BURKIN, DEAN J.; recipient as written: STRYKAGEN CORPORATION, RENO, NV. Optimization of an integrin enhancing molecule source ↗
Aug 25, 2020 NIH award 9R42OD030543-02A1 FY2020: $747,570 awarded for that fiscal year; activity R42 (STTR); PI BURKIN, DEAN J.; recipient as written: STRYKAGEN CORPORATION, RENO, NV. Optimization of an integrin enhancing molecul source ↗
Jun 22, 2018 NIH award 1R41AR073696-01 FY2018: $225,000 awarded for that fiscal year; activity R41 (STTR); PI BURKIN, DEAN J.; recipient as written: STRYKAGEN CORPORATION, RENO, NV. Galectin-1 Protein Therapy for Congenital Muscu source ↗
Jul 7, 2015 NIH award 3R41AR067014-01S1 FY2015: $5,143 awarded for that fiscal year; activity R41 (STTR); PI BURKIN, DEAN J.; recipient as written: STRYKAGEN CORPORATION, RENO, NV. Galectin 1: A novel small protein therapy for D source ↗
Mar 18, 2015 NIH award 1R41AR067019-01A1 FY2015: $224,999 awarded for that fiscal year; activity R41 (STTR); PI BURKIN, DEAN J.; recipient as written: STRYKAGEN CORPORATION, RENO, NV. Optimization of an integrin enhancing molecul source ↗
Aug 28, 2014 NIH award 1R41AR067014-01 FY2014: $219,857 awarded for that fiscal year; activity R41 (STTR); PI BURKIN, DEAN J.; recipient as written: STRYKAGEN CORPORATION, RENO, NV. Galectin 1: A novel small protein therapy for D source ↗